ClinicalTrials.Veeva

Menu
T

The University of Texas MD Anderson Cancer Center | Texas Medical Center - Lymphoma and Myeloma Department

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Atezolizumab
Sapacitabine
Idasanutlin
Alectinib
Pralsetinib
Binimetinib
Bevacizumab
Paclitaxel
Cobimetinib
5-Fluorouracil

Parent organization

This site is a part of The University of Texas MD Anderson Cancer Center

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

19 of 44 total trials

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll...

Enrolling
Metastatic Cancer
Advanced Gastrointestinal Stromal Tumors
Drug: CGT9486
Drug: Sunitinib

This is a Phase 1 study to assess the safety and clinical activity of RO7623066 alone and in combination in patients with advanced solid tumors.

Enrolling
Advanced Solid Tumors
Drug: RO7623066
Drug: Olaparib

This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with elig...

Enrolling
Non-Small Cell Lung Cancer
Drug: Durvalumab
Drug: Entrectinib

This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in com...

Enrolling
Cancer
Drug: Emactuzumab
Drug: Niraparib

This phase 1 study will investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity of AZD0486, a CD19 x CD3 T-cell...

Enrolling
B-cell Non Hodgkin Lymphoma
Follicular Lymphoma
Drug: AZD0486 IV

A Phase Ib/II, open label, multi-center, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor ac...

Active, not recruiting
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
Drug: Linagliptin
Drug: Cobimetinib

Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or me...

Enrolling
Locally Advanced Solid Tumors
Primary CNS Tumors
Drug: Oral repotrectinib (TPX-0005)

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity o...

Enrolling
Small Cell Lung Cancer
Neuroendocrine Carcinoma
Drug: Tocilizumab
Drug: RO7616789

This is a phase I/II, open-label, dose-escalation study designed to evaluate the safety, tolerability, and efficacy of RO7227166 in participants with...

Enrolling
Lymphoma, Non-Hodgkin
Drug: Obinutuzumab
Drug: RO7227166

This is an open-label, multicenter, non-randomized, Phase 2 study to determine the safety, tolerability and efficacy of encorafenib given in combinat...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: encorafenib
Drug: binimetinib

This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 in patients with CLL/SLL or B-cell NHL who have failed or are intolerant...

Enrolling
Waldenstrom Macroglobulinemia
Marginal Zone Lymphoma
Drug: AS-1763

This study is open to people with a type of cancer called dedifferentiated liposarcoma. People with advanced liposarcoma aged 18 or older who are not...

Active, not recruiting
Liposarcoma, Dedifferentiated
Drug: Brigimadlin (BI 907828)
Drug: Doxorubicin

This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusion to participants with re...

Enrolling
Multiple Myeloma
Drug: Cevostamab
Drug: Tocilizumab

A Phase 1a/1b, multicenter, open-label, non-randomized, dose-escalation, and cohort expansion study to examine the DLTs, MTD, and RP2D of SB 11285 ad...

Enrolling
Solid Tumor
Melanoma
Drug: Atezolizumab
Drug: SB 11285

The study objective is to determine the biomarker status of a participant's tumor tissue and use that status to determine eligibility for a linked Ro...

Enrolling
Solid Tumors
Other: Screening platform

A Phase Ib/II, open-label, multicenter, randomized, umbrella study in participants with MIBC and in participants with locally advanced or metastatic...

Enrolling
Bladder Cancer
Urothelial Carcinoma
Drug: Enfortumab Vedotin
Drug: Tiragolumab

Iadademstat is being studied as a treatment for subjects with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like tyrosine kinase m...

Enrolling
Acute Myeloid Leukemia Refractory
Acute Myeloid Leukemia, in Relapse
Drug: Gilteritinib Oral Tablet
Drug: Iadademstat

This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician...

Enrolling
Cholangiocarcinoma
Drug: Physician's Choice
Drug: Tinengotinib 8 mg

TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or imm...

Enrolling
Solid Tumors
Drug: Atezolizumab
Drug: Trastuzumab emtansine

Trial sponsors

Roche logo
Pfizer logo
C
Eisai logo
A
Astellas logo
AstraZeneca logo
Boehringer Ingelheim logo
C
C

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems